Merrill Lynch Is Bullish On Marijuana

Carefully researched, it was an interesting peek at how heavy hitters on Wall Street are starting to view the expanding industry

NEW YORK: The investment arm of Bank of America, Merrill Lynch, sent out a 45 page equity report last week focused on prospects related to marijuana. Carefully researched, it was an interesting peek at how heavy hitters on Wall Street are starting to view the expanding industry. The document is not publicly available. It was leaked to Read the full article…

Marijuana’s Promise Of Profit Remains Elusive (For Now)

Those trials are all ongoing, so investors will need to rely on past trial data to make judgments on whether or not the market demand for GW Pharma's medicine will justify the company's $1.27 billion market cap.

NEW YORK: Excitement surrounding medical marijuana led to a significant run-up in GW Pharmaceuticals‘ share price earlier this year, but based on the company’s recently announced quarterly and fiscal full-year earnings results, the promise of marijuana profit remains far off in the distance. Planning for the future That’s because GW Pharma has only one marketed marijuana derived therapy, Read the full article…

Money And Marijuana: Still No Action From Feds, Washington's Heck Reports

"Every week that passes without new guidance, however, is another week the regulated marijuana markets in Washington and Colorado must operate on a cash-only basis.

WASHINGTON:  Washington Democratic Congressman Denny Heck today issued a statement concerning financial institutions and the business of legal marijuana. Heck’s office reported: “It has been over a year since Washington voters approved I-502. Since that time, officials in our state have worked tirelessly to uphold the will of the voters and implement this law safely and Read the full article…